Navigation Links
Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device
Date:4/7/2008

Innovative Device Recognized for Design Excellence and Patient Ease-of-Use

BROOKFIELD, Wis., April 7, 2008 /PRNewswire-FirstCall/ -- Honeywell (NYSE: HON) today won the 2008 Medical Design Excellence Awards (MDEA) for its Genesis(TM) DM remote patient care device. The Genesis DM won in the rehabilitation and assistive-technology products category.

The award-winning Honeywell HomMed remote patient monitoring device is ideal for both the patient and the medical professional, using text or voice prompts to guide patients through a series of yes/no questions that allow medical professionals to monitor and receive a thorough health assessment.

The Honeywell HomMed remote patient monitoring device is part of the LifeStream Ecosystem and provides patients with an easy-to-use device for the home. The three-part LifeStream ecosystem, providing cost-effective care for patients at home, includes the patient-facing Genesis DM device, software applications and service. Patients suffering from a variety of chronic conditions, such as congestive heart failure, chronic obstructive pulmonary disease, coronary artery disease, diabetes and hypertension, can use the Genesis DM device to assess their condition in the privacy of their homes. This information is transmitted securely over the internet to their caregiver for monitoring and the appropriate intervention if necessary.

"When designing the Genesis DM, we listened to the ultimate customer -- patients. Without more consistent patient use of telemonitoring, the delivery of telehealth cannot be optimized," said Mike Benjamin, president of Honeywell HomMed. "We're honored to receive this recognition and proud of the team at Honeywell HomMed who made this possible. Our focus continues to be ensuring chronically ill patient's independent living with dignity for at an affordable cost."

"It is very important to us to provide our patients and caregivers with the most meaningful information with regards to patient health," said Terry Duesterhoeft, vice president of Marketing & Sales, Honeywell. "As we developed the Genesis DM, we closely evaluated the entire patient environment and discovered that the integration of all data (both objective and subjective) truly differentiated this product in the overall telehealth ecosystem."

The Medical Design Excellence Awards, now in its eleventh year, recognizes companies and individuals worldwide involved in the design, engineering, manufacture or distribution of finished medical devices or medical packaging. Entries are evaluated by a multidisciplinary panel of jurors with expertise in engineering, medicine, industrial design, manufacturing and other design -- and healthcare-related fields.

For more information about Honeywell HomMed's telehealth solutions, visit http://www.hommed.com.

About Honeywell

Honeywell International is a $36 billion diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; and specialty materials. Based in Morris Township, N.J., Honeywell's shares are traded on the New York, London and Chicago Stock Exchanges. For additional information, please visit http://www.honeywell.com.

Forward Looking Statement

This release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of fact, that address activities, events or developments that we or our management intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Forward-looking statements are based on management's assumptions and assessments in light of past experience and trends, current conditions, expected future developments and other relevant factors. They are not guarantees of future performance, and actual results, developments and business decisions may differ from those envisaged by our forward-looking statements. Our forward-looking statements are also subject to risks and uncertainties, which can affect our performance in both the near- and long-term. We identify the principal risks and uncertainties that affect our performance in our Form 10-K and other filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Honeywell
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
2. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
3. Ratcliff Designs Hospital of the Future for John Muir Medical Center - Walnut Creek Campus
4. ATS Medical Expects First Quarter Revenue of $14.6 to $14.8 Million
5. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
6. Tryton Medical, Inc. Closes $14 Million Financing
7. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
8. Boston Biomedical Research Institute Maintains Baa3 Rating from Moodys
9. Varian Medical Systems Schedules Second Quarter FY2008 News Release and Conference Call
10. Galil Medical Announces the Appointment of Martin J. Emerson as President and Chief Executive Officer
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... -- This report analyzes the worldwide markets for Biofuel Enzymes ... Cellulase, and Others. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... of World. Read the full report: ... for the period 2015 through 2022. Also, a six-year historic ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... with catheters associated with peritoneal dialysis, announced today that it has published the ... connection system in Peritoneal Dialysis International (PDI), the official Journal of the ...
(Date:2/18/2017)... Kurzlehrgang mit Fokus auf Assay zum ... metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen dar   ... Wie ... Peretz , Scientific Director bei ImmuneCarta, einen Kurzlehrgang zu ... intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im Rahmen der jährlich ...
(Date:2/17/2017)... , Feb. 17, 2017  BioGenex, a global ... development of a novel system for quantitative immunohistochemistry ... the University of Rochester (NY, USA) and Konica-Minolta ... new system is able to accurately quantify the ... (Human epidermal growth factor receptor-2) in clinical samples. ...
Breaking Biology Technology:
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
(Date:2/7/2017)... WARSAW, Ind. , Feb. 7, 2017 ... global leader in musculoskeletal healthcare, will present at the ... Lotte New York Palace Hotel on Wednesday, February 15, ... A live webcast of the presentation can be accessed ... for replay following the conference via Zimmer Biomet,s Investor ...
Breaking Biology News(10 mins):